Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir - Kevin Robertson; Paul Maruff; Lisa L. Ross; David Wohl; Catherine B Small; Howard Edelstein; Mark S. Shaefer (Journal of NeuroVirology, 2019)

CD4 T cell knockout does not protect against kidney injury and worsens cancer - Kameswaran Ravichandran; Qian Wang; Abdullah Ozkok; Alkesh Jani; Howard Li; Zhibin He; Danica Ljubanovic; Mary C. Weiser-Evans; Raphael A. Nemenoff; Charles L. Edelstein (Journal of Molecular Medicine, 2016)